SUSelami Ulaş

Selami Ulaş

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Selami Ulaş has a total of 34 co-authors. Here are the top co-authors by number of shared publications:

  • Işılay Turan

    Department of Pediatric Allergy and Clinical Immunology, Başakşehir Çam and Sakura City Hospital, Istanbul, Türkiye

    2 shared publications
  • Mehmet Halil Çeliksoy

    Department of Pediatric Allergy and Clinical Immunology, Başakşehir Çam and Sakura City Hospital, Istanbul, Türkiye

    2 shared publications
  • Çiğdem Aydoğmuş

    Department of Pediatric Immunology and Allergy, University of Health Sciences, Basaksehir Cam and Sakura City Hospital, Istanbul, Türkiye

    2 shared publications
  • Ahmet Sert

    Department of Pediatric Allergy and Clinical Immunology, Başakşehir Çam and Sakura City Hospital, Istanbul, Türkiye

    1 shared publication
  • Akif Ayaz

    Genetic Diseases Diagnosis and Evaluation Center, İstinye University, İstanbul, Türkiye

    1 shared publication
  • Alper Gezdirici

    Department of Medical Genetics, Basaksehir Cam and Sakura City Hospital, University of Health Sciences, Istanbul, Turkey

    1 shared publication

Latest Publications

  • Open Access

    A Novel Phosphoglucomutase-3 Gene Variant Causing Milder Phenotype in Two Families

    by Betul Gemici Karaaslan, Mehdi Benamar, Selami Ulas, Sezin Aydemir, Gozde Yesil, Alper Gezdirici, Aysun Ayaz Sari, Serdar Nepesov, Haluk Cokugras, Yildiz Camcioglu, et al.

    Background: Phosphoglucomutase 3 deficiency (PGM3 deficiency) is a rare congenital disorder of glycosylation classically associated with severe immunodeficiency, skeletal abnormalities, and neurodevelopmental impairment. However, emerging evidence suggests that PGM3 deficiency may also present with attenuated or milder clinical phenotypes. In this study, we describe patients with a novel PGM3 variant exhibiting a less severe immunological and clinical presentation, thereby expanding the known phenotypic spectrum of PGM3 deficiency. Methods: Demographic-data and Wechsler Intelligence Scale for Children profiles were evaluated alongside laboratory data, including complete blood cell counts, lymphocyte subsets, serum immunoglobulin levels, vaccine antibody titers, and lymphocyte cytokine profiles. Whole exome sequencing was conducted, and phospho-flow assays were utilized for the analysis of p-STATs. Results: Five patients with a mild form of PGM3 deficiency were described, exhibiting a Hyper-IgE Syndrome phenotype without severe skeletal dysplasia or dysmorphism, with the exception of one patient displaying very mild skeletal dysplasia and three patients exhibiting mild to moderate intellectual disability. All patients demonstrated an increase in Natural Killer T cells and a decrease in B cells, alongside an increase in activated CD4 + T cells (CD45RO+), a decrease in naïve CD4 + and CD8 + T cells (CD45RA+ CCR7+), and an increase in TEMRA CD8 + T cells (CD45RA+CCR7–). Functional analysis of all patients revealed impaired PGM3 function, as evidenced by decreased surface expression of gp130 and p-STAT3. Conclusion: Defective glycosylation in PGM3 deficiency leads to reduced gp130 expression and attenuated gp130-dependent STAT3 phosphorylation. The resulting cellular features partially overlap with those observed in STAT3 loss-of-function and gp130 deficiency, supporting a shared signaling mechanism while remaining clinically distinct.

  • Open Access

    Selective IgA deficiency and allergic diseases: Clinical and immunological evaluation

    by Selami Ulaş, Serdar Al, Sezin Naiboğlu, Işılay Turan, Gülşah Kalay, Nermin Kapçı, Özge Türkyılmaz Uçar, Sibel Kaplan, Erkan Çakmak, Kübra Yırgın, et al.

    Purpose: We aimed to investigate allergic sensitization and associated factors in pediatric patients with selective immunoglobulin A deficiency (SIgAD) and to evaluate differences between allergic and nonallergic groups. Methods: We analyzed 110 patients (aged 4–18 years) diagnosed with SIgAD at Çam and Sakura City Hospitals, Istanbul, between 2021 and 2024. Their demographic, clinical, and laboratory data were assessed. Results: Allergic sensitization was detected in 62.7% of patients. Patients with allergic sensitization, family history of allergic diseases, eosinophilia, and elevated total immunoglobulin E (IgE) levels were significantly higher (P < 0.05). Immunglobulin M (IgM) levels were higher in the allergic group (P = 0.01), and they had lower neutrophil counts (P = 0.03). Allergic sensitization was lower in patients with autoimmune diseases (P = 0.03). In 60% of the patients, the main reason for presentation was recurrent infection. Conclusion: Allergic sensitization with SIgAD is associated with genetic and immunological factors. A family history of allergic disease, eosinophilia, and elevated total IgE levels are important markers for the development of allergy. These findings highlight the need to closely monitor allergies in people with SIgAD.


  • Single Mutation different Clinical Findings: IGLL1 Defect

    by Sezin Naiboğlu, Alper Gezdirici, Selami Ulaş, Işılay Turan, Mehmet Halil Çeliksoy, Çiğdem Aydoğmuş

    Agammaglobulinemia is a rare inherited immunodeficiency disorder characterized by low or absent B cells with absent immunoglobulins. While X-linked agammaglobulinemia (XLA) is the most common type other genetic forms of agammaglobulinemia have been identified. During early childhood, passively transferred maternal Immunoglobulin G protects against various infections. The depletion of these antibodies begins between 6 and 12 months of age, resulting in recurrent sinusitis, bronchitis, and pneumonia in children with X-linked agammaglobulinemia. However, less common autosomal recessive forms of agammaglobulinemia present with more severe clinical features, leading to earlier diagnosis. Herein we present the case of a two-month-old male with IGLL1 gene defect and different clinical findings of family members with the same mutation.